Role of gene polymorphisms in colorectal cancer patients who treated with bevacizumab.

OBJECTIVES

This study aimed to explore the effects of vascular endothelial growth factor A () gene polymorphisms (rs699947 and rs833061) on Bevacizumab (BEV) treatment in colorectal cancer (CRC) patients.

METHODS

125 CRC cases receiving BEV plus FOLFIRI treatment were recruited in this study. polymorphisms were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Correlation of gene polymorphisms with the response rate and progression free survival (PFS) was evaluated. Multivariate analyses were performed to estimate the effects of polymorphisms on the therapeutic effects of BEV treatment in CRC patients.

RESULTS

Rs699947 variants did not show significant association with BEV treatment. For rs833061 analysis, TT and TC genotype carriers had significantly higher ORR (objective response rate) than CC carriers (=0.048 and =0.021, respectively). Moreover, TT carriers underwent a well DCR (disease control rate) compared to CC carriers (=0.002). PFS time also showed obvious correlation with rs833061 polymorphism (log rank test, =0.002). Multivariate analyses demonstrated that TT and TC genotypes of rs833061 polymorphism were significantly correlated with enhanced therapeutic effects and prolonged PFS in CRC patients.

CONCLUSION

rs833061 polymorphism is significantly associated with the therapeutic efficiency of bevacizumab in CRC patients.